AlloSource says study validates science behind its AlloStem bone allograft

Thursday July 7, 2016 0 comments Tags: Centennial, AlloSource, AlloStem, Dr. Nicole Ehrhart, Peter Stevens, CSU Flint Animal Cancer Center

 

CENTENNIAL -- AlloSource, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced a preclinical study showed its AlloStem bone allograft helps stimulate bone formation.AlloSource_logoUSE

Dr. Nicole Ehrhart, professor of surgical oncology at the Colorado State University (CSU) Flint Animal Cancer Center, presented preclinical data on adipose-derived mesenchymal stem cells at the State of Spine Surgery 13th Annual Symposium and will present at the Korean American Spine Society meeting on July 9.

Ehrhart's preclinical study, Adipose-Derived Mesenchymal Stromal Cells Seeded on Demineralized Bone Matrix Persist and Differentiate When Implanted in a Critical-Sized Rat Femur Defect, used similar technology to AlloSource's AlloStem® Cellular Bone Allograft proprietary, patented process.

The preclinical study results showed bone formation within a critical-sized defect in all study subjects. Stem cells were detected for up to 84 days in areas of new formation and differentiated within the bony repair tissue.

"Research is an important part of allograft development and the cellular validation from this study tells a story about AlloStem and its ability to help heal patients," said Peter Stevens, AlloSource's VP of strategy, development and growth.  "We look forward to our continued work with Dr. Ehrhart and CSU to maximize the gift of tissue donation."

AlloStem is partially demineralized allograft bone combined with adipose-derived mesenchymal stem cells. Suitable for general bone grafting applications, AlloStem is similar to autograft bone because it provides the three key properties necessary for bone formation: osteoconduction, osteoinduction and osteogenesis.

"AlloSource has consistently led the field in the quality and quantity of preclinical research behind their cell-based products," said Ehrhart.

"This work is another example of how the company has pursued high quality, hypothesis-driven science to more thoroughly understand how AlloStem promotes bone formation in challenging bone healing environments."

Ehrhart's study has also been accepted for publication in Journal of Biomaterials and Tissue Engineering.